Alle Storys
Folgen
Keine Story von W.O.M. World of Medicine AG mehr verpassen.

W.O.M. World of Medicine AG

euro adhoc: W.O.M. World of Medicine AG
Earnings
WORLD OF MEDICINE will exceed sales and revenue goals for Fiscal Year 2006, and increase planning for 2007

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
11.01.2007
(Berlin, January 11, 2007) Medical device manufacturer WORLD OF
MEDICINE will clearly exceed its goal of a slight revenue increase
for fiscal year 2006, despite implementation of portfolio
streamlining, with total sales of approximately EUR30.8 million (plus
5.8%, 2005: EUR29.1 million). The cost savings achieved through the
"Profit" project were likewise higher than expected. This leads to a
significant improvement in operating income, and an increase in the
pre-tax sales yield. Based on the revised projection, which is based
on actual figures as of the end of November, and which takes the
preliminary figures for December into account, the Management Board
is now forecasting a gross margin of 45% (2005: 31%, plan 2006: 39%).
The anticipated pre-tax sales yield equals approximately 7%  (2005:
-13%, plan 2006: 3%)
For 2007, the Management Board now expects an increase in sales
equivalent to the growth in the market segment (approximately 5%) and
a pre-tax sales yield of approximately 8% (prior: 4%).
The Management Board
WORLD OF MEDICINE and its technologies are paving the way in
Minimally Invasive Surgery - or MIS® for short. The device
manufacturer focuses on private label business and markets its
products through renowned major medical technology firms. WORLD OF
MEDICINE, a well-positioned international firm, exports more than 70
% of its products, and will soon profit from the strong growth
markets outside of Europe. More than 40 % of its sales are transacted
in the U.S., the world’s largest medical technology market. In
addition to this, WORLD OF MEDICINE has made well-timed investments
in the new markets opening in Asia, especially China. Its 30 years of
experience in MIS® are substantiated by the long standing
relationships with private label partners and more than 40 FDA
approvals.  A 50% global market share in the Flow&Fluid business
division, and more than 50 patents underscore its strong technology
and product portfolio. The Stock of WORLD OF MEDICINE (ISIN DE
0006637390) is listed in the Prime Standard at the Frankfurt stock
exchange and in the German Entrepreneurial Index (GEX).
end of announcement                               euro adhoc 11.01.2007 11:02:21

Further inquiry note:

Stefanie Gehrke IR / Verena Zahn Assistant to CFO
Tel.: +49 (0)30 39981 566 / +49 (0)30 39981 642
stefanie.gehrke@womcorp.com / verena.zahn@womcorp.com

Branche: Pharmaceuticals
ISIN: DE0006637390
WKN: 663739
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bayerische Börse / free trade

Weitere Storys: W.O.M. World of Medicine AG
Weitere Storys: W.O.M. World of Medicine AG